MedTrace Logo

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

NCT03525782 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-05-16

No results posted yet for this study

Summary

The study is to assess the safety and efficacy of the anti-MUC1 CAR T cells and /or PD-1 knockout engineered T cells for patients with advanced non-small cell lung cancer.

Conditions

Interventions

BIOLOGICAL

CAR-T Cells

Using the T cells from the patients to produce anti-MUC1 CAR-T Cells and then the cells will be infused back to the patients.

COMBINATION_PRODUCT

CAR-T combining PD-1 Knockout

Using the T cells from the patients to prepare anti-MUC1 CAR-T Cells and PD-1 knockout T cells, then the cells will be infused back to the patients

BIOLOGICAL

PD-1 knockout

Using the T cells from the patients to prepare PD-1 knockout T cells, then the cells will be infused back to the patients

DRUG

PD-1 mAb

Patients will be treated with an identical course with a FDA approved monoclonal antibody against PD-1

OTHER

Sham control

Patient's T cell will treated ex vivo with modification and then infused back in a similar time course.

Sponsors & Collaborators

  • Guangzhou Anjie Biomedical Technology Co., Ltd.

    collaborator INDUSTRY

  • University of Technology, Sydney

    collaborator OTHER

  • The First Affiliated Hospital of Guangdong Pharmaceutical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-01
Primary Completion
2021-01-31
Completion
2022-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03525782 on ClinicalTrials.gov